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Abstract
Mastitis in a single quarter can cause high somatic cell counts (SCC), clinical mastitis, and death in dairy cows.
Currently, management of these mastitic quarters presents a problem for the dairy industry. Casein hydrolysate (CH)
is an intramammary (IMM) infusion treatment reported to induce mammary involution. The primary objectives of this
study were to investigate whether IMM CH treatment of single high SCC quarters, followed by cessation of quarter
milk production for the remainder of lactation, was effective in reducing cow–level SCC and whether that quarter
resumed milk production following calving. Three treatment groups were used: CH, non-hydrolyzed casein (NHC),
and cessation of milking only (negative; N). Treatments were assigned in a 2:2:1 ratio for 40 cows enrolled in the
study; 27 cows completed the entire protocol. Following IMM infusion and involution of the single mastitic quarter,
decreases in cow–level SCC (-966,000/ml) and milk production (-11 lb (5 kg), -14%) with 3 remaining lactating
quarters were significant for all 28 cows combined. Cows treated with CH (n=17) had a significant decrease in cow–
level SCC (-1,150,000/ml) during remaining lactation. All treated quarters returned to milk production after calving,
and their proportion of total–cow milk production (24%) was not different than before treatment (28%). After calving,
treated quarters’ decrease in SCC was significant for CH (-2,763,000/ml; n=14) and N (–5,324,000/ml; n=5). Of 16
quarters with positive milk culture before treatment that completed the protocol, 88% (14/16) were cured (no
isolation of the same bacteria for 3 weeks following calving). A new intramammary infection (IMI) was detected in
67% (18/27) of previously treated quarters post-calving. Infusing single mastitic quarters with casein hydrolysate to
induce involution for the remainder of lactation may be a promising alternative to current methods.

remove them from the herd altogether. However, many times these
animals are pregnant and/or otherwise productive dairy cows, so
producers simply cease milk production in the high SCC quarter. In
SCC:
Somatic
Cell
Count;
IMM:
Intramammary;
Abbreviations:
CH: Casein Hydrolysate, NHC: Non-Hydrolyzed Casein, N: Cessation modern high–producing dairy cows this can sometimes be difficult to
achieve without causing permanent damage to the quarter or other
N: Cessation of Milking of Milking Only, Negative; IMI: Intramammary
adverse effects on the animal [6,7]. High–yielding cows with high SCC
Infection; BTSCC: Bulk Tank Somatic Cell Count; DHIA: Dairy Herd
milk from one quarter or recurring mastitis episodes in a single
Improvement Association; DIM: Days in Milk, CMT: California
quarter, commonly lead producers to the management practice of
Mastitis Test
attempting to remove the affected quarter by intramammary infusion
(IMM) of caustic substances such as strong iodine (e.g. 2% to 7%
iodine) or 2% chlorhexidine [8]. Previous studies have shown efficacy
Introduction
of these methods for cessation of milk production in a single
Mastitis is the most expensive disease complex in the dairy industry. mammary quarter but both iodine and chlorhexidine were reported to
Costs include lost milk production, antibiotic treatment, discarded induce undesired consequences [9]. Use of strong iodine was
milk because of antibiotic therapy, and death loss. Reduced bulk tank associated with no return to production, essentially creating a
milk quality and milk price also result from increased white blood permanently “three–quartered” cow. Intramammary chlorhexidine
cells, reported as somatic cell count (SCC), being shed into milk by resulted in some cows regaining full use of the treated quarter in the
affected quarters. The goal is to maintain a bulk tank SCC<200,000/ml subsequent lactation but antimicrobial residue was detected 35 to 42
[1-3]. A single mastitic quarter may have an individual SCC of millions days post infusion by Delvotest® [10] validating the concern that
per milliliter of milk, impacting the cow-level and bulk tank milk SCC. accidental milking of an infused “dry” quarter could lead to
Previous studies have documented the negative impact that single antimicrobial residue violations in bulk milk. Therefore, the off–label
quarters with extremely elevated SCC can have on the overall quality of IMM of chlorhexidine is not recommended as a method for ceasing
bulk tank milk [4]. Most dairy producers receive economic benefit milk production in a quarter.
from maintaining a low bulk tank somatic cell count (BTSCC) and
An earlier study found IMM of casein hydrolysate effective in
understand the advantage of diverting high SCC milk from chronically
inflamed quarters from entering the bulk tank [5]. If cows with a single inducing involution of the mammary gland without systemic disease
quarter causing high SCC in their composite milk are undesirable for or causing permanent quarter damage [11]. Casein hydrolysates are
other health or production reasons, the decision may be made to milk–borne factors believed to be part of the biological pathway which
causes involution in the bovine mammary gland, 40-70 days prior to
Keywords: Dairy; Mastitis; Management; SCC; Milk quality
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expected parturition. Intramammary infusion of casein hydrolysates
has been demonstrated to locally induce involution within a single
quarter, as a management strategy for cessation of lactation in quarters
with a persistently elevated SCC or repeated episodes of mastitis,
without the consequences of antimicrobial residues and/or permanent
mammary gland destruction.
The basis for this study was to address the need for managing
mastitic quarters mid-lactation in otherwise healthy dairy cows.
Currently, there is no widely accepted method available for producers
to use on these animals. This shortfall has resulted in unsatisfactory
outcomes. The primary objective was to evaluate cessation of milking
in individual mastitic quarters using intramammary infusion of CH, in
comparison with intramammary infusion of a placebo or no infusion.

Material and Methods
Selection of study cows
Study cows were selected from 6 commercial Idaho dairy farms. All
cows were housed in outdoor, shaded dry lot pens typical of dairy
farms in that region. Participating farms were on a twice per day
milking schedule and following a regular monthly dairy herd
improvement association (DHIA) testing schedule [12]. Lactation
number, SCC, pregnancy status, days until expected dry off date, days
until expected calving and daily milk production data were obtained
from DHIA records. To be eligible, cow–level SCC ≥ 500,000/ml,
confirmed pregnant, ≥ 35 days before scheduled dry–off date,
estimated 95–220 days until expected calving, and daily milk
production ≥ 50 lb (22.7 kg) were required.
Cows meeting eligibility requirements were then screened for
quarter–level IMI using the California Mastitis Test (CMT) [13]. For
trial inclusion, CMT scores of 2-plus in a single quarter and Negative
or Trace in the other 3 quarters were required. Using aseptic sampling
technique, an individual milk sample was collected from the quarter
with an elevated CMT score, along with a pooled milk sample of the
other three quarters. An aliquot of the individual quarter sample was
used for microbial culture, while the remainder of the quarter sample
and the pooled sample of the other quarters were both tested for SCC.
Somatic cell count was measured by use of the FossomaticTM
automatic cell counter [14]. An SCC of ≥ 1,000,000/ml in the single
mastitic quarter, SCC ≤ 400,000/ml in the 3 non–mastitic quarters, and
Mycoplasma spp.–negative culture results finalized enrollment in the
study.
Using a completely randomized block design, cows were blocked by
lactation number (1st, 2nd–plus) and mastitic quarter culture result
(growth, no growth), for a total of 4 blocks. There were 3 treatment
groups: casein hydrolysate (CH), non–hydrolyzed casein (NHC), and
cessation of milking only (negative; N). Cows were randomly assigned
to treatment groups within each block, in a 2:2:1 proportion due to the
challenges of obtaining a large sample size and in a purposeful
determination to allot most of the animals to the CH and NHC
treatment groups.

Milk microbiology
Milk sample bacterial cultures were completed according to
standard methods [15,16]. In brief, an inoculum of 10 µl of milk was
plated on washed cow blood agar and placed in a standard, non–CO2
incubator at 37°C for 48 h. Plates were examined by laboratory
technicians at 24 and 48 h for bacterial growth; organism identification
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was determined by colony morphology and biochemical secondary
tests on any isolates found.

Preparation of casein hydrolysate
Two batches of casein hydrolysate were prepared using aseptic
technique. Each batch was prepared using 100 g of commercially
purchased bovine casein powder dissolved in 1 L of autoclaved
deionized water containing 3 g of TRIS buffer and enzymatically
digested with Trypsin. After digestion, remaining particulate material
was removed via two centrifugation cycles of 15 minutes at 3000 xg.
Solution was boiled for 15 minutes between centrifugation cycles to
denature any remaining enzyme and kill possible environmental
contaminant bacteria, followed by sterilization using vacuum
membrane filtration. The final product was dispensed (15 ml) into
sterile syringes and stored frozen at –20°C. Two batches of NHC
solution were produced following the same methods as above but
omitting enzymatic digestion, thus preventing hydrolysis.
Each batch of casein hydrolysate or NHC was screened for bacterial
contamination by inoculating tryptic soy broth with 1 ml of solution,
incubating for 24 h and inoculating blood agar. Blood agar plates were
incubated for a total of 48 h at 37°C and read at 24 and 48 h for
bacterial growth. A separate blood agar plate was plated directly with
100 µl of non–enriched solution and then incubated and examined in
the same way. The definition of an uncontaminated batch was no
growth of any bacterial colonies on either direct or enriched cultures.
Protein concentration of each batch was quantified using a
bicinchoninic acid (BCA) assay, according to the manufacturer’s
instructions. The BCA assay is commonly used for protein
quantification [17]. Final protein concentration of CH solutions was
1.5 mg/ml, which resulted in 22.5 mg per 15 ml dose. Final
concentration of NHC was 0.2 mg/ml, which resulted in 3 mg/15 ml
dose. Each batch was also assessed for purity by running a sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) gel.

Milk weight collection
Mastitic quarter contribution to total-cow milk production was
measured by bucket milking on Day 1 of the 48 h treatment protocol.
Animals were milked into a clear, graduated, 80 lb (36.3 kg) capacity
bucket in two steps: the three healthy quarters were milked together
first, followed by the single mastitic quarter. This allowed measurement
of milk production from the total cow for that milking and the
proportional contribution of the mastitic quarter. This bucket milking
process was repeated at a single milking, between 10-21 days in milk
(DIM) in the subsequent lactation, to evaluate the milk production and
proportion of total–cow milk from the mastitic quarter.

Treatment administration
All mastitic quarters were milked once per day for the 3-day
treatment period. Each animal had all 4 quarters milked in the
morning, followed by infusion of the mastitic quarter with the assigned
treatment (CH or NHC) or no infusion (N), followed by skipping the
evening milking of that mastitic quarter. This process was repeated at
24 h (day 2) and again at 48 h (day 3) for the third and final treatment.
This gradual cessation of milking was intended to cease milk
production in the target quarter with minimal discomfort and risk of
adverse effects to the animal. The mastitic quarter was not milked
again for the remainder of the lactation. Somatic cell count data from
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the 3 remaining quarters was obtained from the next DHIA test
following treatment.

Evaluation of intramammary infections following dry period
Bacteriological cure of previous IMI and new infection rates were
not primary objects of this study. However, involution is a mechanism
of clearing existing IMI during the dry period [18,19] and this is an
important outcome for any treatment during the dry period in dairy
cattle. After calving the previously treated quarters were resampled 3
times, once per week at 1-7 DIM, 8-14 DIM and 15-21 DIM. Resulting
case definitions were: Cure=all 3 post–calving cultures negative for any
bacteria isolated from the pre–treatment sample; Chronic IMI=any
bacteria isolated from the pre–treatment sample, followed by isolation
of the same bacteria from at least one post–calving culture. New
IMI=one or more bacteria not isolated from the pre–treatment sample,
followed by isolation from at least one post–calving culture sample
(multiple bacterial species only count as one IMI).

Statistical analysis
Statistical analyses were performed using GraphPad Prism version
7.01 and SAS Studio. Descriptive statistics were calculated. To evaluate
for possible confounding, pre–treatment variables were compared
among the 3 treatment groups. The continuous variables DIM, days
until expected dry–off, cow–level SCC, mastitic quarter SCC, total–
cow milk production, and proportion of treated quarter contribution
to total–cow milk weight were evaluated for possible differences
between treatment groups using analysis of variance (ANOVA). The
grand means of cow–level SCC, mastitic quarter SCC, total–cow milk
production, and mastitic quarter milk production (including
comparison between all front and rear quarters) were compared pre–
and post–treatment using a t–test. Means of the continuous variables
cow–level SCC, mastitic quarter SCC, total–cow milk production and
quarter proportion of total–cow milk were compared pre– and post–
treatment between treatment groups using ANOVA.
The change in each of the above outcome variables from pre– to
post–treatment was tested for significance within each group, also
using ANOVA. For the continuous variables DIM, DCC, pre–
treatment SCC of total cow and individual quarter, pre–treatment milk
weight of total cow and individual quarter and contribution of the
individual quarter to the total cow production, association with post–
treatment SCC in the remaining three quarters was evaluated using
multiple regression (PROC REG). Input variables that might logically
be associated with the outcome variable–log of post–treatment SCC in

the remaining 3 lactating quarters–were evaluated in both a linear
mixed model (PROC GLIMMIX, SAS Studio) and a general linear
model (PROC GLM, SAS Studio). Initial models included all logical
potential input variables followed by backward elimination until the
final model included only input variables with P<alpha. The categorical
outcomes of Cure, Chronic IMI, and New IMI were compared for
significant differences between the categorical variable treatment
groups using Chi–square. Alpha was 0.05 for all statistical analyses.

Results
Forty cows (Holstein n=38, Jersey n=2) were initially enrolled in the
study. Their single mastitic quarters (5 right front, 8 left front, 14 right
rear, 13 left rear), were randomly assigned among the 3 treatment
groups (2:2:1 ratio). There were 18, 15 and 7 cows in the CH, NHC and
N treatment groups, respectively. Six cows were in 1st lactation and 34
were in 2nd–plus lactation, 23 treated quarters had bacteria isolated
pre–treatment, while 17 quarters had no growth on culture. All 40
mastitic quarters were successfully dried off, without any reports of
adverse effects to the animal (e.g., swelling, edema, milk leakage, etc.).
Before they could calve again, 12 cows were sold (4 CH, 6 NHC, 2 N
treated cows) because of mastitis (n=3), abortion (n=5), infertility
(n=2) or died from displaced abomasum complications (n=2). One
cow died before her third post–calving culture sample could be
collected; cause of death was unknown. Therefore, 27 cows finished the
entire study protocol. However, the last cow who died contributed data
for all other outcome variables, so for most outcomes, there were 28
cows, with the final distribution of animals per treatment group: CH
(n=14), NHC (n=9) and N (n= 5). All treated quarters of the cows that
remained in the study resumed milk production following the next
calving.
There were no statistically significant differences between cows
assigned to treatment groups for the following parameters: DIM
(CH=264, NHC=219, N=222), days carried calf (DCC) (CH=115,
NHC=102, N=86), pre–treatment cow–level SCC (CH=1,792,000/ml,
NHC=1,464,000/ml, N=1,590,000/ml), mastitic quarter SCC
(CH=4,363,000/ml, NHC=3,745,000/ml, N=5,852,000/ml), total–cow
milk production before treatment (CH=79 lb [36 kg], NHC=74 lb [34
kg], N=86 lb [39 kg]) and proportion of mastitic quarters’ contribution
to total–cow milk production (CH=26%, NHC=28%, N=32%) (all
P>0.5 ANOVA, Table 1). The average length of the dry period for the
treated quarters was 181, 177 and 151 days for CH, NHC and N,
respectively (P>0.14, ANOVA).

Measurement/treatment group

Pre-

Post-

Cow SCC-Casein ( x 1000 cells/ml)

a1792

(n=18)

e642

P-value ≠

Change£

(n=17)

0.003

i-1150

Cow SCC-Non-hydrolyzed casein ( x 1000 cells/ml)

a1464

(n=15)

e755

(n=15)

0.08

i-709

Cow SCC-Negative ( x 1000 cells/ml)

a1590

(n=7)

e546

(n=7)

0.08

i-1044

Qtr. SCC-Casein ( x 1000 cells/ml)

b4363

(n=18)

f1600(n=14)

0.0002

j–2763

Qtr. SCC-Non–hydrolyzed casein ( x 1000 cells/ml)

b3745

(n=15)

f1616

0.01

j-2129

Qtr. SCC-Negative ( x 1000 cells/ml)

b5852

(n=7)

f528

<0.0001

j-5324

Total milk-Casein (kg)

c36

0.2

k-4
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(n=18)

g32

(n=9)

(n=5)

(n=17)
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Total milk-Non-hydrolyzed casein (kg)

c34

(n=15)

g27

(n=15)

0.04

k-7

Total milk-Negative (kg)

c39

(n=7)

g36

(n=7)

0.57

k-3

Qtr.% of total Cow-Casein

d26

(n=18)

h24.5

0.6

l-1.5

Qtr.% of total Cow-Non-hydrolyzed casein

d28

(n=15)

h22

(n=9)

0.17

l-6

Qtr. % of total Cow-Negative

d32

(n=7)

h27

(n=5)

0.41

l-5

Cow SCC ( x 1000 cells/ml)-All cows

1634 (n=40)

668 (n=39)

0.0002

-966

Qtr. SCC ( x 1000 cells/ml)-All cows

4392 (n=40)

1414 (n=28)

<0.0001

-2978

Cow Milk Yield (lb)-All cows

78 (n=40)

67 (n=39)

0.02

-11

(n=14)

≠ For test of significance of difference from pre– to post–treatment, within each treatment group
£ Change in measurement (post minus pre), post–infusion
Means with same letter were not significantly different between treatment groups (p>0.05, ANOVA)

Table 1: Pre and post-treatment comparisons of cow–level SCC, quarter SCC, total–cow milk and quarter percentage of total–cow milk by
treatment group and overall.
Following treatment (leaving 3 remaining lactating quarters), mean
cow–level SCC was 668,000/ml and mean milk production was 67 lb
(30 kg) for all 39 cows who survived to the next monthly DHIA test
(Table 1). For those 39 cows, the decreases in cow–level SCC (–
966,000/ml; P=0.0002) and in total–cow milk production, –11 lb (–5
kg, –14%; P=0.02) were statistically significant, as tested by students t–
test (Table 1). No statistical significance was found for the effects of
DIM, pre–treatment cow–level SCC, pre–treatment mastitic quarter
SCC, total–cow milk production or individual quarter contribution on
post–treatment SCC, as tested in the multiple regression models.
The final general linear model was significant (P ≤ 0.001) with
R2=0.65. The input (explanatory) variables pre–treatment cow–level
SCC, bacterial agent, lactation number (1st, 2nd–plus), treatment, and
interaction of treatment and lactation number were all significantly
associated with the outcome variable, log of post–treatment SCC in the
remaining 3 lactating quarters (all P ≤ 0.02). The same variables with
the same P values were also detected as significant in the final mixed
model. Higher pre–treatment cow–level SCC was associated with
lower post–treatment SCC in the 3 remaining quarters, and this was
particularly evident among cows infected with several bacterial agents.
For the following agents, pre–treatment cow–level SCC and post–
treatment SCC in the 3 remaining quarters, respectively were: E. coli,
1,780,000/ml, 1,436,000/ml; no growth, 1,731,000/ml, 841,000/ml;
Staphylococcus spp., 1,089,000/ml, 436,000/ml. The treatment effect
and its interaction with lactation number were driven by cows in first
lactation; their post–treatment means of SCC in the 3 remaining
quarters by treatment were: CH=1,020,000/ml, NHC=90,000/ml,
N=1,000/ml. In contrast, for cows in 2nd–plus lactation, the post–
treatment means of SCC in the 3 remaining quarters were:
CH=561,000/ml, NHC=857,000/ml, N=637,000/ml.
Within treatment groups, the decrease in total–cow milk production
following involution of the mastitic quarter was not significant except
for the decrease from 74 lb (34 kg) to 59 lb (27 kg) in the 15 NHC
treated cows (P=0.04, ANOVA, Table 1). All 28 treated quarters in the
cows who calved again returned to milk production after calving; mean
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SCC of the 28 quarters was 1,414,000/ml, significantly decreased (–
2,978,000/ml; P=<0.0001, Table 1) and their contribution to total–cow
milk production was 24%, not different from their 28% contribution
during the previous lactation before treatment (P=0.46, student’s t–
test). Front or rear quarters did not differ significantly in outcomes (all
P>0.6, ANOVA).
Cow–level SCC during the remainder of lactation decreased
significantly following treatment with CH in the mastitic quarter (–
1,150,000/ml [n=17]; P=0.003, Table 1). Following calving and
resumption of milk production, significant decreases in SCC in the
previously treated mastitic quarters were observed within all three
treatment groups (CH: –2,763,000/ml [n=14], P=0.0002; NHC: –
2,129,000/ml [n=9], P=0.01; N:–5,324,000/ml [n=5]; P<0.0001, all
ANOVA, Table 1). All other pre–versus post–treatment comparisons
by treatment group were not statistically significant.

Bacterial isolation, cures and new intramammary infections
The pre–enrollment milk culture screening found a pathogenic
bacterial organism in 23/40 (58%) mastitic quarters. The predominant
organisms isolated were Streptococcus spp. (n=10) and coagulase–
negative Staphylococcus spp. (n=5). Also isolated were Escherichia coli
(n=3), Staphylococcus aureus (n=3) and Pseudomonas spp. (n=1),
unknown pathogen (n=1). Of the 23 cows whose mastitic quarters had
bacteria isolated, 16 finished the study and were available for
evaluation of bacterial cure or persistence; 14/16 (88%) quarters had a
bacteriological Cure (Table 2). Of the 27 cows who calved again and
survived to have all 3 post–calving milk cultures, 18/27 (67%)
contracted a New IMI in the previously involuted quarter.
Treatment groups were not significantly different in their outcomes
of Cure or Chronic IMI, (all P ≥ 0.35, Fisher’s exact test). There were
significantly fewer new IMI among cows treated with CH (P=0.046,
Fisher’s exact test). For cows in the NHC and N treatment groups, the
proportion of New IMI was not significantly different from that for all
cows (P ≥ 0.19).
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Pre-Treatment Culture (n=40)

Post-Treatment Culture (n=27)

Treatment Group

Culture-positive

Culture- negative

Previously positive

Previously negative

Chronic IMI1

IMI Cured2

New IMI3

CH+

10

8

7

6

(0/7) 0%

(7/7) 100%

(6/13) 46%

NHC+

9

6

6

3

(1/6) 17%

(5/6) 83%

(8/9) 88%

N+

4

3

3

2

(1/3) 33%

(2/3) 67%

(4/5) 80%

Totals

23£

17

16§

11

(2/16) 12%

(14/16) 88%

(18/27) 67%

1Chronic

IMI=any bacteria isolated from the pre–treatment sample, followed by isolation of the same bacteria from at least one post–calving culture

2Cure=all
3New

3 post–calving cultures negative for any bacteria isolated from the pre–treatment sample

IMI=one or more bacteria not isolated from the pre–treatment sample, followed by isolation from at least one

+CH=Casein
£23/40

hydrolysate; NHC=Non–hydrolyzed casein; N=cessation of milking only, Negative.

Cows had a mastitis organism present pre–treatment; 16 remained in the study long enough for 3 post–treatment sample collection

§27/40

cows completed the study with 3 post–treatment cultures; 11 of these did not have a mastitis organism present pre–treatment, which left 16 cows eligible to be
chronic IMI or cured

Table 2: Bacteriological cures and new infections by treatment group.

Discussion
After involution of a single mastitic quarter with high SCC, cows
produced a mean of 86% of their previous total production from the 3
remaining lactating quarters at the time of their next monthly DHIA
test. Postpartum, all cows resumed milk production with the treated
quarters contributing a mean of one–fourth of total–cow production.
The average decrease of 1,100,000/ml in cow–level SCC following
involution of a single mastitic quarter, and the reduction of SCC in
mastitic quarters by over 2.5 million/ml when their milk production
resumed after calving provides support for IMM casein hydrolysate as
a management option to create three–quartered cows to enhance milk
quality. Interestingly, our analysis identified that first lactation cows
varied considerably in post–treatment SCC among the treatment
groups, resulting in a highly significant interaction between treatment
and lactation. Among older cows, which comprised majority of cows
in the dataset, there were no significant differences in cow–level SCC
between treatment groups. In many cases, mammary involution is
believed to be a contributor to the spontaneous cure of previous IMIs
from one lactation to the next [20]. By design, the mastitic quarters in
our study were dry for longer than the typical dry period of
approximately 60 days [21], with more than 200 days in some cases.
Bacterial cure was observed in over 85% of the treated and involuted
quarters in this study, while two–thirds contracted a new IMI while
dry. Average IMI prevalence reported in early lactation cows ranges
from 10%–29% [22–24]. A limitation of this study was a relatively
small sample size, which was due to logistics and expense.
The results of this study indicate that IMM use of CH may be a
promising alternative to traditional methods of treating mastitis. Some
disadvantages of using conventional intramammary antibiotic
treatment for mastitis include the potential for antibiotic residues, the
milk lost due to required withhold times and the increasingly negative
consumer perception of antibiotic use in food animal management.
Additionally, many bacterial organisms that are responsible for causing
mastitis are not susceptible to antibiotics and for that reason; do not
warrant treatment with such. Milk cessation in individual quarters
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using IMM CH is a novel approach to mastitis management, which
utilizes the natural process of tissue rebuilding that, occurs during
mammary involution, without any use of intramammary antibiotics.
This method could potentially extend the productive life of many dairy
animals, without jeopardizing milk quality or causing adverse physical
effects.

Conclusion
This study evaluated three methods for cessation of milking of a
single mastitic quarter mid–lactation to attempt to improve cow–level
milk quality. None of the animals showed any signs of pain or physical
distress in response to drying off the quarter. All treated quarters
returned to adequate milk production, with the favorable outcome of
prolonged life of lactating cows. Cessation of production in the chronic
mastitic quarters resulted in a decrease in cow–level SCC for all treated
animals, regardless of treatment, which indicates this is an appropriate
milk quality management tool.
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